{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:27:03Z","timestamp":1767972423929,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["16\/2020"],"award-info":[{"award-number":["16\/2020"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["302637\/2021-4"],"award-info":[{"award-number":["302637\/2021-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Estado de S\u00e3o Paulo","award":["2021\/09857-8"],"award-info":[{"award-number":["2021\/09857-8"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11419-022-00646-6","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T09:02:52Z","timestamp":1665219772000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The mystery behind the apprehensions of the selective cannabinoid receptor type-2 agonist BZO-HEXOXIZID (MDA-19) as a drug of abuse"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-9326","authenticated-orcid":false,"given":"Karen Rafaela Gon\u00e7alves","family":"de Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Luis","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz F.","family":"Neves J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falio","family":"de Carvalho Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Learth","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luiz","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Yonamine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"646_CR1","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1021\/JM8002203","volume":"51","author":"P Diaz","year":"2008","unstructured":"Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M (2008) Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J Med Chem 51:4932\u20134947. https:\/\/doi.org\/10.1021\/JM8002203","journal-title":"J Med Chem"},{"key":"646_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1515\/MED-2018-0061","volume":"13","author":"N Dang","year":"2018","unstructured":"Dang N, Meng X, Ma S, Zhang Q, Sun X, Wei J, Huang S (2018) MDA-19 suppresses progression of melanoma via inhibiting the PI3K\/Akt pathway. Open Med 13:416\u2013424. https:\/\/doi.org\/10.1515\/MED-2018-0061","journal-title":"Open Med"},{"key":"646_CR3","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181501","author":"B Liu","year":"2018","unstructured":"Liu B, Xu L, Dai E, Tian JX, Li JM (2018) Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K\/Akt\/mTOR signaling pathway. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20181501"},{"key":"646_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/S13062-019-0241-1","author":"M Rao","year":"2019","unstructured":"Rao M, Chen D, Zhan P, Jiang J (2019) MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway. Biol Direct. https:\/\/doi.org\/10.1186\/S13062-019-0241-1","journal-title":"Biol Direct"},{"key":"646_CR5","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.1007\/S12035-019-1637-8","volume":"56","author":"D Schubert","year":"2019","unstructured":"Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P (2019) Efficacy of cannabinoids in a pre-clinical drug-screening platform for Alzheimer\u2019s disease. Mol Neurobiol 56:7719\u20137730. https:\/\/doi.org\/10.1007\/S12035-019-1637-8","journal-title":"Mol Neurobiol"},{"key":"646_CR6","volume-title":"Europol 2016 Annual Report on the implementation of council decision 2005\/387\/JHA. Implementation reports","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2017","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2017) Europol 2016 Annual Report on the implementation of council decision 2005\/387\/JHA. Implementation reports. Publications Office of the European Union, Luxembourg"},{"key":"646_CR7","unstructured":"Benschop A, Bujalski M, Dabrowska K, Demetrovics Z, Egger D, Felinczi K, Wouters M (2017) New Psychoactive Substances: transnational project on different user groups, user characteristics, extent and patterns of use, market dynamics, and best practices in prevention, NPS-transnational Project. https:\/\/hdl.handle.net\/11245.1\/9fa41897-9c42-4996-ac40-00913accd089."},{"key":"646_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/DTA.3185","volume":"14","author":"CM Liu","year":"2022","unstructured":"Liu CM, Hua ZD, Jia W, Li T (2022) Identification of AD-18, 5F-MDA-19, and pentyl MDA-19 in seized materials after the class-wide ban of synthetic cannabinoids in China. Drug Test Anal 14:307\u2013316. https:\/\/doi.org\/10.1002\/DTA.3185","journal-title":"Drug Test Anal"},{"key":"646_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2018_160","volume":"252","author":"M Evans-Brown","year":"2018","unstructured":"Evans-Brown M, Sedefov R (2018) Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol 252:3\u201349. https:\/\/doi.org\/10.1007\/164_2018_160","journal-title":"Handb Exp Pharmacol"},{"key":"646_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/978-0-387-76678-2_38","volume-title":"Drug addiction: from basic research to therapy","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. Drug addiction: from basic research to therapy. Springer, New York, pp 637\u2013686"},{"key":"646_CR11","volume-title":"UNODC early warning advisory on new psychoactive substances February 2022\u2013UNODC EWA: new synthetic cannabinoid receptor agonists increase structural diversity","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2022","unstructured":"United Nations Office on Drugs and Crime (UNODC) (2022) UNODC early warning advisory on new psychoactive substances February 2022\u2013UNODC EWA: new synthetic cannabinoid receptor agonists increase structural diversity. UNODC, Vienna. https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/5f3dab83-8486-4fff-acd4-94b6e83b2452"},{"key":"646_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10408444.2020.1762539","volume":"50","author":"VL Alves","year":"2020","unstructured":"Alves VL, Gon\u00e7alves JL, Aguiar J, Teixeira HM, C\u00e2mara J (2020) The synthetic cannabinoids phenomenon: from structure to toxicological properties. Rev Crit Rev Toxicol 50:359\u2013382. https:\/\/doi.org\/10.1080\/10408444.2020.1762539","journal-title":"Rev Crit Rev Toxicol"},{"key":"646_CR13","volume-title":"European drug report 2021: trends and developments","author":"European monitoring centre for drugs and drug addiction","year":"2021","unstructured":"European monitoring centre for drugs and drug addiction (2021) European drug report 2021: trends and developments. Publications Office of the European Union, Luxemborg"},{"key":"646_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/J.FSISYN.2020.11.003","author":"JN Tettey","year":"2021","unstructured":"Tettey JN, Crean C, Rodrigues J, Yap TWA, Lim JLW, Lee HZS, Ching M (2021) United nations office on drugs and crime: recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists in seized materials. Forensic Sci Int. https:\/\/doi.org\/10.1016\/J.FSISYN.2020.11.003","journal-title":"Forensic Sci Int"},{"key":"646_CR15","volume-title":"New systematic naming for synthetic cannabinoid \u201cMDA-19\u201d and its related analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID","author":"RM Schelkun","year":"2021","unstructured":"Schelkun RM, Krotulski AJ, Iula DM, Logan BK (2021) New systematic naming for synthetic cannabinoid \u201cMDA-19\u201d and its related analogues: BZO-HEXOXIZID, 5F-BZO-POXIZID, and BZO-POXIZID. CFSRE Cayman Chemical, Ann Arbor"},{"key":"646_CR16","unstructured":"Minist\u00e9rio da Sa\u00fade (ANVISA) DC (2022) Diretoria Colegiada. (2022) Resolu\u00e7\u00e3o - RDC no. 598, de 9 de Fevereiro de 2022"},{"key":"646_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1471-4892(02)00004-8","volume":"3","author":"TP Malan Jr","year":"2003","unstructured":"Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003) CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3:62\u201367. https:\/\/doi.org\/10.1016\/S1471-4892(02)00004-8","journal-title":"Curr Opin Pharmacol"},{"key":"646_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/APS.2016.149","volume":"38","author":"DJ Chen","year":"2017","unstructured":"Chen DJ, Gao M, Gao FF, Su QX, Wu J (2017) Brain cannabinoid receptor 2: expression, function and modulation. Acta Pharmacol Sin 38:312\u2013316. https:\/\/doi.org\/10.1038\/APS.2016.149","journal-title":"Acta Pharmacol Sin"},{"key":"646_CR19","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/S00213-017-4669-7","volume":"234","author":"T Ahmad","year":"2017","unstructured":"Ahmad T, Laviolette SR (2017) Cannabinoid reward and aversion effects in the posterior ventral tegmental area are mediated through dissociable opiate receptor subtypes and separate amygdalar and accumbal dopamine receptor substrates. Psychopharmacology 234:2325\u20132336. https:\/\/doi.org\/10.1007\/S00213-017-4669-7","journal-title":"Psychopharmacology"},{"key":"646_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1021\/ED080P214","volume":"80","author":"BT Burlingham","year":"2003","unstructured":"Burlingham BT, Widlanski TS (2003) An intuitive look at the relationship of Ki and IC50: a more general use for the Dixon plot. Jof Chem Educ 80:214\u2013218. https:\/\/doi.org\/10.1021\/ED080P214","journal-title":"Jof Chem Educ"},{"issue":"1","key":"646_CR21","first-page":"218","volume":"265","author":"DR Compton","year":"1993","unstructured":"Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharm Exp Therap 265(1):218\u2013226","journal-title":"J Pharm Exp Therap"},{"key":"646_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0376-8716(99)00152-0","volume":"60","author":"MM Aung","year":"2000","unstructured":"Aung MM, Griffin G, Huffman JW, Wu MJ, Keel C, Yang B, Martin BR (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend 60:133\u2013140. https:\/\/doi.org\/10.1016\/S0376-8716(99)00152-0","journal-title":"Drug Alcohol Depend"},{"key":"646_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1213\/ANE.0B013E3181E0CDAF","volume":"111","author":"JJ Xu","year":"2010","unstructured":"Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M (2010) Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg 111:99\u2013109. https:\/\/doi.org\/10.1213\/ANE.0B013E3181E0CDAF","journal-title":"Anesth Analg"},{"key":"646_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1124\/JPET.108.145011","volume":"328","author":"BB Yao","year":"2009","unstructured":"Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, Meyer MD (2009) Characterization of a cannabinoid CB 2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]- Amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J PharmExp Therap 328:141\u2013151. https:\/\/doi.org\/10.1124\/JPET.108.145011","journal-title":"J PharmExp Therap"},{"key":"646_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuropharm.2013.07.022","volume":"75","author":"JL Wiley","year":"2013","unstructured":"Wiley JL, Marusich JA, Lefever TW et al (2013) Cannabinoids in disguise: \u03949-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology 75:145\u2013154. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.022","journal-title":"Neuropharmacology"},{"key":"646_CR26","doi-asserted-by":"publisher","DOI":"10.1039\/D1MD00242B","author":"E Sparkes","year":"2022","unstructured":"Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, Banister SD (2022) Structure\u2013activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Med Chem. https:\/\/doi.org\/10.1039\/D1MD00242B","journal-title":"RSC Med Chem"},{"key":"646_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.EJMECH.2014.07.062","volume":"85","author":"O Rosati","year":"2014","unstructured":"Rosati O, Messina F, Pelosi A, Curini M, Petrucci V, Gertsch J, Chicca A (2014) One-pot heterogeneous synthesis of \u03943-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB1 and CB2 receptors. Euro J Med Chem 85:77\u201386. https:\/\/doi.org\/10.1016\/J.EJMECH.2014.07.062","journal-title":"Euro J Med Chem"},{"key":"646_CR28","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1046\/J.1471-4159.1999.0722379.X","volume":"72","author":"CS Kearn","year":"1999","unstructured":"Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ (1999) Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP\/GTP exchange. J Neurochem 72:2379\u20132387. https:\/\/doi.org\/10.1046\/J.1471-4159.1999.0722379.X","journal-title":"J Neurochem"},{"issue":"4","key":"646_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/antiox11040660","volume":"11","author":"DM Kopustinskiene","year":"2022","unstructured":"Kopustinskiene DM, Masteikova R, Lazauskas R, Bernatoniene J (2022) Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants 11(4):660. https:\/\/doi.org\/10.3390\/antiox11040660","journal-title":"Antioxidants"},{"key":"646_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/JAT\/BKAB088","author":"P Kavanagh","year":"2021","unstructured":"Kavanagh P, Pechnikov A, Nikolaev I, Dowling G, Kolosova M, Grigoryev A (2021) Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver. J Anal Tox. https:\/\/doi.org\/10.1093\/JAT\/BKAB088","journal-title":"J Anal Tox"},{"key":"646_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.FORSCIINT.2022.111209","author":"J de Carvalho Ponce","year":"2022","unstructured":"de Carvalho Ponce J, Junior LFNN, da Silva ACS, Liberatori LC, de Medeiros PV (2022) Detection of cocaine crystals dispersed on non-Erythroxylum herbs. Forensic Sci Int. https:\/\/doi.org\/10.1016\/J.FORSCIINT.2022.111209","journal-title":"Forensic Sci Int"},{"key":"646_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/J.BRAINRESREV.2008.12.003","volume":"60","author":"P Anand","year":"2009","unstructured":"Anand P, Whiteside G, Fowler CJ, Hohmann AG (2009) Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60:255\u2013266. https:\/\/doi.org\/10.1016\/J.BRAINRESREV.2008.12.003","journal-title":"Brain Res Rev"},{"key":"646_CR33","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1073\/PNAS.0409888102","volume":"102","author":"MM Ibrahim","year":"2005","unstructured":"Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Malan TP Jr (2005) CB2 cannabinoid receptor activation produces anti-nociception by stimulating peripheral release of endogenous opioids. PNAS 102:3093\u20133098. https:\/\/doi.org\/10.1073\/PNAS.0409888102","journal-title":"PNAS"},{"key":"646_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinetics 42:327\u2013360. https:\/\/doi.org\/10.2165\/00003088-200342040-00003","journal-title":"Clin Pharmacokinetics"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-022-00646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-022-00646-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-022-00646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T15:24:36Z","timestamp":1674055476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-022-00646-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s11419-022-00646-6","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animal performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}